Key result
Among 281 surveyed physicians across seven countries, 83% had knowledge of selective imidazoline receptor agonists and 70% prescribed them regularly, typically as a third-line strategy.
Why the study?
To evaluate contemporary hypertension management strategies in countries with high prescription rates of selective imidazoline receptor agonists (SIRAs) to better understand their real-world rationale and practical indications.
Cross-Sectional (n=281)
Yes
In surveyed countries, selective imidazoline receptor agonists are commonly prescribed as third-line antihypertensive therapy, often combined with RAS-inhibitors, driven by considerations of sympathetic inhibition.
BACKGROUND: Multiple pharmacologic strategies are currently available to lower blood pressure (BP). Renin-angiotensin system (RAS)-inhibitors, calcium channel blockers and diuretics are widely recommended as first line therapies. Sympathetic activation is an important contributor to BP elevation but remains unopposed or is even increased by some of these drug classes. Selective imidazoline receptor agonists (SIRAs) reduce increased central sympathetic outflow and are considered as add-on therapy in most guidelines. We conducted an international survey to evaluate contemporary hypertension management strategies in countries with high prescription rates of SIRAs to better understand the rationale and practical indications for their use in a real-world setting. METHODS: Physicians from seven countries (India, Jordan, Lebanon, Russia, Saudi Arabia, South Africa, United Arab Emirates) were asked to complete a web-based questionnaire and comment on clinical case scenarios to provide information on their current practice regarding antihypertension strategies, underlying rationale for their choices, and adherence to relevant guidelines. RESULTS: 281 physicians completed the questionnaire including mainly cardiologists (35%) and general practitioners (32%). 96% reported using European (60%) or local (56%) guidelines in their daily practices. The majority of responding physicians (83%) had knowledge of SIRAs and 70% prescribed SIRAs regularly typically as a third line antihypertensive strategy (63%). The preferred combination partners for SIRAs were RAS-inhibitors (72%). CONCLUSIONS: Contemporary hypertension management varies between countries and therapeutic approaches in a real-world setting are not always in line with recommendations from available guidelines. In the countries selected for this survey prescription of SIRAs was common and appeared to be guided predominantly by considerations relating to the underlying pathophysiologic mechanism of sympathetic inhibition.
No takes yet. Share an insight, caveat, or question.
Schlaich et al. (2020) conducted a cross-sectional in Hypertension (n=281). Selective imidazoline receptor agonists (SIRAs) was evaluated on Regular prescription of SIRAs. Among 281 surveyed physicians across seven countries, 83% had knowledge of selective imidazoline receptor agonists and 70% prescribed them regularly, typically as a third-line strategy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: